These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30396947)

  • 1. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
    Fu S; Lin J
    Anticancer Res; 2018 Nov; 38(11):6271-6279. PubMed ID: 30396947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Fu S; Chen X; Lo HW; Lin J
    Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
    Fu S; Chen X; Lin HJ; Lin J
    Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
    Chen X; Tian J; Su GH; Lin J
    Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Zhang R; Roque DM; Reader J; Lin J
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bazedoxifene Inhibits Cell Viability, Colony-Forming Activity, and Cell Migration in Human Non-Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine.
    Huang Y; Lin J; Fu X; Li L; Fu S
    Clin Respir J; 2024 Aug; 18(8):e13822. PubMed ID: 39152779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    Zhang R; Wang T; Lin J
    Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
    Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
    Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression.
    Youness RA; Assal RA; Abdel Motaal A; Gad MZ
    Nitric Oxide; 2018 Nov; 80():12-23. PubMed ID: 30081213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.